Cargando…

Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma

BACKGROUND: Despite recent advances in the therapy for adenocarcinoma of the esophagogastric junction (AEG), overall prognosis remains poor. Programmed cell death protein 1 (PD1) is a co-inhibitory receptor primarily expressed by T-cells. Tumor cells can escape anticancer immune responses by trigger...

Descripción completa

Detalles Bibliográficos
Autores principales: Kollmann, Dagmar, Ignatova, Desislava, Jedamzik, Julia, Chang, Yun-Tsan, Jomrich, Gerd, Paireder, Matthias, Kristo, Ivan, Kazakov, Dmitry, Michal, Michal, Cozzio, Antonio, Hoetzenecker, Wolfram, Schatton, Tobias, Asari, Reza, Preusser, Matthias, Guenova, Emmanuella, Schoppmann, Sebastian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539275/
https://www.ncbi.nlm.nih.gov/pubmed/28429196
http://dx.doi.org/10.1245/s10434-017-5858-7
_version_ 1783254457895616512
author Kollmann, Dagmar
Ignatova, Desislava
Jedamzik, Julia
Chang, Yun-Tsan
Jomrich, Gerd
Paireder, Matthias
Kristo, Ivan
Kazakov, Dmitry
Michal, Michal
Cozzio, Antonio
Hoetzenecker, Wolfram
Schatton, Tobias
Asari, Reza
Preusser, Matthias
Guenova, Emmanuella
Schoppmann, Sebastian F.
author_facet Kollmann, Dagmar
Ignatova, Desislava
Jedamzik, Julia
Chang, Yun-Tsan
Jomrich, Gerd
Paireder, Matthias
Kristo, Ivan
Kazakov, Dmitry
Michal, Michal
Cozzio, Antonio
Hoetzenecker, Wolfram
Schatton, Tobias
Asari, Reza
Preusser, Matthias
Guenova, Emmanuella
Schoppmann, Sebastian F.
author_sort Kollmann, Dagmar
collection PubMed
description BACKGROUND: Despite recent advances in the therapy for adenocarcinoma of the esophagogastric junction (AEG), overall prognosis remains poor. Programmed cell death protein 1 (PD1) is a co-inhibitory receptor primarily expressed by T-cells. Tumor cells can escape anticancer immune responses by triggering the PD1 pathway. Moreover, PD1 receptor engagement on cancer cells may trigger tumor-intrinsic growth signals. This study aimed to evaluate the potential clinical relevance of PD1 expression by tumor-infiltrating lymphocytes (TILs) and cancer cells in the AEG. METHODS: Patients with AEG who underwent esophagectomy from 1992 to 2011 were included in the study. Expression of PD1was evaluated by immunohistochemistry and correlated with long-term overall survival (OS), disease-free survival (DFS), and various clinicopathologic parameters. RESULTS: Tumor biospecimens from 168 patients were analyzed. In the analysis, 81% of the patients showed high tumoral frequencies (>5%) of PD1-expressing TILs (TIL-PD1(+)), and 77% of patient tumors harbored high levels (>5%) of PD1(+) cancer cells (cancer-PD1(+)). Expression of PD1 by TILs and cancer cells correlated significantly (p < 0.05) with patients’ tumor stage and lymph node involvement. Compared with the patients who had low tumoral frequencies of PD1(+) TILs or cancer cells, the TIL-PD1(+) and cancer-PD1(+) patients demonstrated significantly reduced DFS in the univariate analysis (5-year DFS: 73.3 vs. 41.9%, log-rank 0.008 and 71.3 vs. 41.6%, p = 0.008, respectively). Additionally, the cancer-PD1(+) patients showed significantly decreased OS in the univariate analysis compared with the cancer-PD1(−) patients (5-year OS: 68.8 vs. 43.5%; p = 0.047). However, these correlations did not reach significance in the multivariate analysis. CONCLUSIONS: The PD1 receptor is expressed by both TILs and cancer cells in AEG. High expression of PD1 is associated with advanced tumor stage and lymph node involvement, but not with survival.
format Online
Article
Text
id pubmed-5539275
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-55392752017-08-17 Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma Kollmann, Dagmar Ignatova, Desislava Jedamzik, Julia Chang, Yun-Tsan Jomrich, Gerd Paireder, Matthias Kristo, Ivan Kazakov, Dmitry Michal, Michal Cozzio, Antonio Hoetzenecker, Wolfram Schatton, Tobias Asari, Reza Preusser, Matthias Guenova, Emmanuella Schoppmann, Sebastian F. Ann Surg Oncol Gastrointestinal Oncology BACKGROUND: Despite recent advances in the therapy for adenocarcinoma of the esophagogastric junction (AEG), overall prognosis remains poor. Programmed cell death protein 1 (PD1) is a co-inhibitory receptor primarily expressed by T-cells. Tumor cells can escape anticancer immune responses by triggering the PD1 pathway. Moreover, PD1 receptor engagement on cancer cells may trigger tumor-intrinsic growth signals. This study aimed to evaluate the potential clinical relevance of PD1 expression by tumor-infiltrating lymphocytes (TILs) and cancer cells in the AEG. METHODS: Patients with AEG who underwent esophagectomy from 1992 to 2011 were included in the study. Expression of PD1was evaluated by immunohistochemistry and correlated with long-term overall survival (OS), disease-free survival (DFS), and various clinicopathologic parameters. RESULTS: Tumor biospecimens from 168 patients were analyzed. In the analysis, 81% of the patients showed high tumoral frequencies (>5%) of PD1-expressing TILs (TIL-PD1(+)), and 77% of patient tumors harbored high levels (>5%) of PD1(+) cancer cells (cancer-PD1(+)). Expression of PD1 by TILs and cancer cells correlated significantly (p < 0.05) with patients’ tumor stage and lymph node involvement. Compared with the patients who had low tumoral frequencies of PD1(+) TILs or cancer cells, the TIL-PD1(+) and cancer-PD1(+) patients demonstrated significantly reduced DFS in the univariate analysis (5-year DFS: 73.3 vs. 41.9%, log-rank 0.008 and 71.3 vs. 41.6%, p = 0.008, respectively). Additionally, the cancer-PD1(+) patients showed significantly decreased OS in the univariate analysis compared with the cancer-PD1(−) patients (5-year OS: 68.8 vs. 43.5%; p = 0.047). However, these correlations did not reach significance in the multivariate analysis. CONCLUSIONS: The PD1 receptor is expressed by both TILs and cancer cells in AEG. High expression of PD1 is associated with advanced tumor stage and lymph node involvement, but not with survival. Springer International Publishing 2017-04-20 2017 /pmc/articles/PMC5539275/ /pubmed/28429196 http://dx.doi.org/10.1245/s10434-017-5858-7 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Gastrointestinal Oncology
Kollmann, Dagmar
Ignatova, Desislava
Jedamzik, Julia
Chang, Yun-Tsan
Jomrich, Gerd
Paireder, Matthias
Kristo, Ivan
Kazakov, Dmitry
Michal, Michal
Cozzio, Antonio
Hoetzenecker, Wolfram
Schatton, Tobias
Asari, Reza
Preusser, Matthias
Guenova, Emmanuella
Schoppmann, Sebastian F.
Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
title Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
title_full Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
title_fullStr Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
title_full_unstemmed Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
title_short Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
title_sort expression of programmed cell death protein 1 by tumor-infiltrating lymphocytes and tumor cells is associated with advanced tumor stage in patients with esophageal adenocarcinoma
topic Gastrointestinal Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539275/
https://www.ncbi.nlm.nih.gov/pubmed/28429196
http://dx.doi.org/10.1245/s10434-017-5858-7
work_keys_str_mv AT kollmanndagmar expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT ignatovadesislava expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT jedamzikjulia expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT changyuntsan expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT jomrichgerd expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT pairedermatthias expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT kristoivan expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT kazakovdmitry expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT michalmichal expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT cozzioantonio expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT hoetzeneckerwolfram expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT schattontobias expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT asarireza expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT preussermatthias expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT guenovaemmanuella expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma
AT schoppmannsebastianf expressionofprogrammedcelldeathprotein1bytumorinfiltratinglymphocytesandtumorcellsisassociatedwithadvancedtumorstageinpatientswithesophagealadenocarcinoma